Epcoritamab for Follicular Lymphoma

DC
Overseen ByDai Chihara, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.

Who Is on the Research Team?

DC

Dai Chihara, MD

Principal Investigator

UT MD Anderson Cancer Center

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
Agree to refrain from donating blood while on study treatment, during dose interruptions and for at least 12 months following last dose
I have not received any systemic treatment for my lymphoma.
See 18 more

Exclusion Criteria

I have had lung inflammation needing steroids or currently have lung inflammation.
Life expectancy less than 6 months
Psychiatric illness or social situations limiting compliance with study requirements
See 16 more

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: OBS ArmExperimental Treatment1 Intervention
Group II: EPCORI ArmExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Genmab

Industry Sponsor

Trials
76
Recruited
15,300+

Dr. Jan van de Winkel

Genmab

Chief Executive Officer since 2010

PhD in Immunology, University of Utrecht

Dr. Judith Klimovsky

Genmab

Chief Medical Officer since 2019

MD, University of Copenhagen